Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-18
2005-01-18
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S218000, C514S272000, C514S273000, C540S544000, C540S575000, C544S320000, C544S321000
Reexamination Certificate
active
06844335
ABSTRACT:
A pyrimidone derivative represented by formula (I) or a salt thereof:Wherein:R1 represents a hydrogen atom or a C1-6alkyl group which may be substituted by a C6,10aryl group;R2 represents a C1-10alkyl group which may be substituted, a C2-6alkenyl group which may be substituted, a C3-6alkynyl group which may be substituted, a C3-6cycloalkyl group which may be substituted, or a C6-10ARYL group which may be substituted;or R1 and R2 form together a C2-6alkylene group which may be substituted;or R1 and R2 form together a chain of formula —(CH2)2—X—(CH2)2— or —(CH2)2—X—(CH2)3— where X represents a oxygen atom, a sulfur atom, or a nitrogen atom which may be substituted;R3 represents a 2, 3 or 4-pyridyl group optionally substituted by a C1-4alkyl group, C1-4alkoxy group or halogen atom; andR4 represents a C1-10alkyl group optionally substituted by a hydroxyl group, amino, C1-6monoalkylamino group, C2-12dialkylamino group or C6,10aryl group which may be substituted.And a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β such as Alzheimer's disease.
REFERENCES:
patent: 4460589 (1984-07-01), Wierenga et al.
patent: 07 435631 (1974-09-01), None
patent: 07 435633 (1974-09-01), None
patent: 49-035631 (1974-09-01), None
patent: WO 98 24780 (1998-06-01), None
patent: WO 00 18758 (2000-04-01), None
Julien et al., PubMed Abstract (Prog Nucleic Acid Res Mol Biol. 61:1-23), 1998.*
Liu et al., PubMed Abstract (J Neurochem 87(6):1333-44), Dec. 2003.*
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1992-1996, 1996.*
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.*
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.*
Chemical Abstracts, vol. 84, No. 7, Feb. 16, 1976, Columbus, OH, p. 502, Abstract No. 44112b.
Chemical Abstracts, vol. 83, No. 1, Jul. 7, 1975, Columbus, OH, p. 853, Abstract No. 10127z.
H.I. Skulnick, et al.; “Pyrimidinones.3.N-Substituted 6-Phenylpyrimidinones and Pyrimidinediones with Diuretic/Hypotensive and Antiinflammatory Activity”; J. Med. Chem., vol. 29, No. 8, 1986, pp 1499-1504.
H.I. Skulnick, et al.; “Pyrimidinones.1.2 Amino-5-halo-6-aryl-4(3H)-pyrimidinones. Interferon-Inducing Antiviral Agents”; J. Med. Chem., vol. 28, No. 12, 1985, pp 1864-1869.
H.J. Kabbe; “Substituierte 4-Hydroxy-und 4-Amino-pyrimidine”; Liebigs Ann. Chem.; vol. 704; 1967; pp 144-149.
Almario Garcia Antonio
Ando Ryoichi
Arimoto Keiichi
Frost Jonathan Reid
Li Adrien Tak
Alexander Michael D.
Dupont Paul E.
Mitsubishi Pharma Corporation
Rao Deepak
Sanofi-Synthelabo
LandOfFree
2-amino-3-(alkyl)-pyrimidone derivatives as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-amino-3-(alkyl)-pyrimidone derivatives as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-amino-3-(alkyl)-pyrimidone derivatives as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435160